Bipolar disorder or manic-depressive illness, is a brain disorder that causes unusual shifts in mood and activity levels such as periods of depression and elevated mood which is known as mania or hypomania.

Portland, OR -- (SBWire) -- 08/01/2017 --Bipolar disorder or manic-depressive illness, is a brain disorder that causes unusual shifts in mood and activity levels such as periods of depression and elevated mood which is known as mania or hypomania. In addition, this disorder is differentiated as manic episodes and depressive episodes. The patients suffering from bipolar disorders experience serious shifts in mood, energy, and thinking. The disorders involve periods of mania at one point (such as have racing thoughts, have lots of energy), to the lows of depression at the other (such as feeling of sadness or apathy). The global bipolar disorder market is expected to grow at a CAGR of 3.2% from 2017 to 2025.

Request Sample At: https://www.progressivemarkets.com/industry-research/bipolar-disorder-market

Based on drug class, the global bipolar disorder market is segmented as mood stabilizers, anticonvulsants, atypical antipsychotics, antidepressant drugs, and anti-anxiety drugs. Based on mechanism of action, it is classified as selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, tricyclic antidepressants, Monoamine oxidase inhibitors, benzodiazepines, beta blockers, and others. By geography, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Market Dynamics

Drivers

Rise in number of bipolar disorders cases.
Growth in public awareness about infertility.

Technological advancements in bipolar disorder treatment.

Enquire About Report At: https://www.progressivemarkets.com/enquiry-about-report/bipolar-disorder-market

Restraints

Stringent regulations and adverse drug reactions of anticonvulsants.

Unapproved bipolar drugs.
Market Players

The top players in the global bipolar disorder market include Otsuka, Pfizer, Janssen pharmaceuticals, Ferrer, Allergan, Abbott Laboratories Inc., Bristol-Myers Squibb Company, AstraZeneca PLC, Cephalon Inc., Eli Lilly and Company, Dainippon Sumitomo Pharma Co. Ltd., Forest Laboratories Inc., GlaxoSmithKline PLC, Gedeon Richter PLC, H. Lundbeck A/S, Merck & Co., Inc., and others.

Request Customization At:https://www.progressivemarkets.com/request-customization/bipolar-disorder-market

Table Of Contents:
1. Executive summary
1.1. Key Findings
1.2. Market Attractiveness and Trend analysis
1.3. Competitive Landscape and recent industry development analysis
2. Introduction
2.1. Report Description
2.2. Scope and Definitions
2.3. Research Methodology
3. Market landscape
3.1. Growth Drivers
3.1.1. Impact Analysis
3.2. Restrains and Challenges
3.2.1. Impact Analysis
3.3. Porter's Analysis
4. Global Bipolar Disorder Market by Drug class
4.1. Mood stabilizers
4.1.1. Historical Market Size by Region, 2014-2016
4.1.2. Market Forecast by Region, 2017-2025
4.2. Anticonvulsants